EUVIMEDEUVIMED entdecken
Open Access

Real-world Impact of the 21-Gene Recurrence Score on Adjuvant Treatment Decisions in Early Breast Cancer

Nobuyoshi Kittaka, Namiko Tanaka, Chisato Takeuchi, Kana Anno

In Vivo · 2026-11 · 40 (6) · 3678-3684

DOI: 10.21873/invivo.14506 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, online erschienen am 29.10.2026. Verfasst von Nobuyoshi Kittaka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Osaka Rosai Hospital, Osaka, Japan kittaka-no@osakah.johas.go.jp. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local, Biomarkers, Tumor. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: The 21-gene recurrence score (RS) assay guides adjuvant chemotherapy decisions in hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer. We evaluated how RS results altered treatment recommendations and were integrated with clinicopathological factors in routine practice. PATIENTS AND METHODS: We retrospectively analyzed 41 consecutive patients who underwent RS testing for postoperative treatment planning at a single institution. Pre-test and post-test treatment recommendations were compared. Exploratory analyses examined patients with RS ≤25 who received chemotherapy and treatment patterns in node-positive disease. RESULTS: Median age was 58 years; 20 patients (48.8%) had node-positive disease. RS was 0-10 in nine patients (22.0%), 11-25 in 25 (61.0%), and ≥26 in 7 (17.1%). Treatment recommendations changed in 16 patients (39.0%): chemotherapy was omitted in 13 (31.7%) and added in 3 (7.3%). Among 34 patients with RS ≤25, 29 (85.3%) received endocrine therapy alone and 5 (14.7%) received chemo-endocrine therapy. Patients receiving chemotherapy were younger (median 48 vs. 59 years, p=0.049) and had higher RS values (median 17 vs. 13, p=0.007). Among 20 node-positive patients, 15 (75.0%) received endocrine therapy alone. CONCLUSION: RS testing altered adjuvant treatment recommendations in 39.0% of patients, predominantly through chemotherapy omission. In patients with RS ≤25, younger age and higher RS were associated with chemotherapy use, suggesting that genomic and clinicopathological information were integrated in routine decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasm Recurrence, LocalBiomarkers, TumorHumansFemaleChemotherapy, AdjuvantMiddle AgedAgedAdultNeoplasm StagingRetrospective StudiesGene Expression Profiling

Stichwörter der Autor:innen

Breast cancerOncotype DXchemotherapyrecurrence scoretreatment decision-making

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Breast Surgery, Osaka Rosai Hospital, Osaka, Japan kittaka-no@osakah.johas.go.jp.
  • Department of Breast Surgery, Osaka Rosai Hospital, Osaka, Japan.

Zitieren

APA

Kittaka, N., Tanaka, N., Takeuchi, C., & Anno, K. (2026). Real-world Impact of the 21-Gene Recurrence Score on Adjuvant Treatment Decisions in Early Breast Cancer. In Vivo, 40(6), 3678-3684. https://doi.org/10.21873/invivo.14506

Vancouver

Kittaka N, Tanaka N, Takeuchi C, Anno K. Real-world Impact of the 21-Gene Recurrence Score on Adjuvant Treatment Decisions in Early Breast Cancer. In Vivo. 2026;40(6):3678-3684. doi:10.21873/invivo.14506

BibTeX
@article{Kittaka2026,
  author = {Kittaka, Nobuyoshi and Tanaka, Namiko and Takeuchi, Chisato and Anno, Kana},
  title = {Real-world Impact of the 21-Gene Recurrence Score on Adjuvant Treatment Decisions in Early Breast Cancer},
  journal = {In Vivo},
  year = {2026},
  volume = {40},
  number = {6},
  pages = {3678--3684},
  doi = {10.21873/invivo.14506}
}
Kostenlos starten →